We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
- Authors
Bonomi, P; Kim, K; Fairclough, D; Cella, D; Kugler, J; Rowinsky, E; Jiroutek, M; Johnson, D
- Abstract
Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Vol 18, Issue 3, p623
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2000.18.3.623